Edgewise Therapeutics Inc

NASDAQ EWTX

Data sourced from

and

Daily

Download Data

Edgewise Therapeutics Inc Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024

Edgewise Therapeutics Inc Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.

Edgewise Therapeutics Inc 52-week high Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Edgewise Therapeutics Inc 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Edgewise Therapeutics Inc average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is NA.

NASDAQ: EWTX

Edgewise Therapeutics Inc

CEO	Dr. Kevin Koch Ph.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	3415 Colorado Avenue, Boulder, CO, United States, 80303
Employees	92
Sector	Healthcare
Industry	Biotechnology

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Key trends